Literature DB >> 10498657

Immune selection and genetic sequence variation in core and envelope regions of hepatitis C virus.

J M Christie1, H Chapel, R W Chapman, W M Rosenberg.   

Abstract

How Hepatitis C Virus (HCV) causes persistent infection is unknown. One hypothesis is that HCV evades the host immune response through mutation in immune epitopes. We have investigated mutations in the HCV genome to see if they cluster within immune epitopes; and we have studied the effect of antibody deficiency on mutation rates. We studied patients with chronic hepatitis C, 3 with antibody deficiency and 3 with normal immunity. Regions of the core and envelope genes of HCV, encoding cytotoxic (CTL), and B cell epitopes were sequenced at 2 time points, 2 years apart. The diversity of quasispecies increased with time. The HCV genetic mutation rate was higher than previously predicted. The cryptic nucleotide mutation rate in core was similar to that observed in envelope, suggesting that the error rate of the HCV RNA polymerase is similar in both regions. In contrast, the coding mutation rate was decreased in core and increased in envelope. No genetic mutation was seen in any of the core CTL epitopes despite detectable cellular responses. All patients had mutations within a previously described envelope CTL epitope but did not exhibit immune responses to either index or mutated peptides. There was no difference in mutation rates in any cellular or humoral epitopes between patients with antibody deficiency and normal immunity. Thus we have found no evidence that mutations were selected by T-lymphocytes or antibodies. These findings implicate alternative virus-host interactions in the selection of HCV mutations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10498657     DOI: 10.1002/hep.510300403

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  13 in total

1.  Influence of increased CD4 cell counts on the genetic variability of hepatitis C virus in patients co-infected with human immunodeficiency virus I.

Authors:  Xue-Ping Wang; Leslie Goodwin; Pamela Kahn; Craig Gawel; Cheston B Cunha; Benjamin Laser; Benjamin Sahn; Mark H Kaplan
Journal:  J Biomol Tech       Date:  2006-07

2.  Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome: an accelerated approach toward epitope-driven vaccine development.

Authors:  Karim M Abdel-Hady; Andres H Gutierrez; Frances Terry; Joe Desrosiers; Anne S De Groot; Hassan M E Azzazy
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Wide range of quasispecies diversity during primary hepatitis C virus infection.

Authors:  Belinda L Herring; Rose Tsui; Lorraine Peddada; Michael Busch; Eric L Delwart
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 4.  Sequence diversity of hepatitis C virus: implications for immune control and therapy.

Authors:  Joerg Timm; Michael Roggendorf
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

5.  Detection of inhibition of bovine viral diarrhea virus by aromatic cationic molecules.

Authors:  M Daniel Givens; Christine C Dykstra; Kenny V Brock; David A Stringfellow; Arvind Kumar; Chad E Stephens; Hakan Goker; David W Boykin
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

6.  Within-host dynamics of the hepatitis C virus quasispecies population in HIV-1/HCV coinfected patients.

Authors:  Flavia Bernini; Erika Ebranati; Chiara De Maddalena; Renata Shkjezi; Laura Milazzo; Alessandra Lo Presti; Massimo Ciccozzi; Massimo Galli; Gianguglielmo Zehender
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

7.  CD8 epitope escape and reversion in acute HCV infection.

Authors:  Joerg Timm; Georg M Lauer; Daniel G Kavanagh; Isabelle Sheridan; Arthur Y Kim; Michaela Lucas; Thillagavathie Pillay; Kei Ouchi; Laura L Reyor; Julian Schulze zur Wiesch; Rajesh T Gandhi; Raymond T Chung; Nina Bhardwaj; Paul Klenerman; Bruce D Walker; Todd M Allen
Journal:  J Exp Med       Date:  2004-12-20       Impact factor: 14.307

8.  Evaluation of cellular responses for a chimeric HBsAg-HCV core DNA vaccine in BALB/c mice.

Authors:  Maryam Yazdanian; Arash Memarnejadian; Mehdi Mahdavi; Fatemeh Motevalli; Seyed Mehdi Sadat; Rouhollah Vahabpour; Hossein Khanahmad; Hoorieh Soleimanjahi; Agata Budkowska; Farzin Roohvand
Journal:  Adv Biomed Res       Date:  2015-01-06

9.  Design of an epitope-based peptide vaccine against spike protein of human coronavirus: an in silico approach.

Authors:  Arafat Rahman Oany; Abdullah-Al Emran; Tahmina Pervin Jyoti
Journal:  Drug Des Devel Ther       Date:  2014-08-21       Impact factor: 4.162

10.  Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding.

Authors:  Katharina B Rothwangl; Balaji Manicassamy; Susan L Uprichard; Lijun Rong
Journal:  Virol J       Date:  2008-03-20       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.